Boundless Bio Secures $100M Series C Funding to Advance ecDNA-Directed Therapies for Oncogene Cancer

San Diego, CA, May 16, 2023 (Business Wire) -- Boundless Bio, a pioneering precision oncology company, has successfully raised $100 million in a Series C financing round led by Leaps by Bayer and RA Capital Management. Boundless Bio is focused on leveraging the potential of extrachromosomal DNA (ecDNA) to develop transformative therapies for patients with previously intractable oncogene amplified cancers.

Read full article here.